Literature DB >> 8934384

Microalbuminuria in essential hypertension and diabetes mellitus.

H H Parving1.   

Abstract

DEFINITION: Microalbuminuria is defined as abnormally elevated urinary albumin excretion below the level of clinical albuminuria (albustix). This represents a urinary albumin excretion rate of 20-200 micrograms/min, equal to 30-300 mg/24 h. Urinary albumin excretion can vary as much as 40% with natural fluctuations, and so several tests should be done. Inexpensive radioimmunoassay, enzyme-linked immunosorbent assays or immunoturbidimetric assays are now routine in many clinical laboratories. PREVALENCE: The prevalence of microalbuminuria in essential hypertension and diabetes is about the same: 25% (range 14-31) and 20% (9-27), respectively. MECHANISMS: Increased transglomerular passage is the major mechanism of microalbuminuria in both the above-mentioned conditions; increased hydraulic glomerular capillary pressure and glomerular lesions probably both contribute. Microalbuminuria is highly predictive of the development of diabetic nephropathy but the predictive power in relation to hypertensive nephropathy remains to be established. However, in both conditions microalbuminuria is associated with an increased risk of retinopathy, left ventricular hypertrophy, fatal and non-fatal cardiovascular disease and all-cause mortality. The following mechanisms have been suggested as a link between microalbuminuria and these findings: endothelial dysfunction, insulin resistance, hyperinsulinemia, dyslipoproteinemia and a procoagulant state. EFFECT OF ANTIHYPERTENSIVE TREATMENT: Blood pressure lowering reduces microalbuminuria in essential hypertension and in diabetes mellitus. Long-term studies in diabetes suggest that angiotensin converting enzyme inhibitors postpone, and may even prevent, progression to overt clinical nephropathy in normotensive diabetic patients with persistent microalbuminuria. So far, there have been no long-term comparative trials on the beneficial effects of different antihypertensive drugs in hypertensive patients with microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934384     DOI: 10.1097/00004872-199609002-00017

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  12 in total

1.  The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.

Authors:  Taco B M Monster; Wilbert M T Janssen; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study.

Authors:  Francesca Viazzi; Giovanna Leoncini; Novella Conti; Cinzia Tomolillo; Giovanna Giachero; Marina Vercelli; Giacomo Deferrari; Roberto Pontremoli
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

Review 3.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  Second manifestations of ARTerial disease (SMART) study: rationale and design.

Authors:  P C Simons; A Algra; M F van de Laak; D E Grobbee; Y van der Graaf
Journal:  Eur J Epidemiol       Date:  1999-10       Impact factor: 8.082

Review 5.  Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.

Authors:  George L Bakris; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 6.  Drug treatment of hypertension complicating diabetes mellitus.

Authors:  M J MacLeod; J McLay
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

7.  Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus.

Authors:  Ichiro Wakabayashi; Hiroshi Masuda
Journal:  J Thromb Thrombolysis       Date:  2007-10-11       Impact factor: 2.300

8.  Incidence of microalbuminuria in hypertensive patients.

Authors:  Ravjit Kaur Sabharwal; Parduman Singh; M M Arora; B L Somani; Vivek Ambade
Journal:  Indian J Clin Biochem       Date:  2008-03-06

9.  Urinary N-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy.

Authors:  Vivek Ambade; Parduman Sing; B L Somani; Dashrath Basanna
Journal:  Indian J Clin Biochem       Date:  2006-09

10.  Endothelins and markers of renal damage in recently diagnosed hypertensive patients.

Authors:  Antonia Maldonado-Martín; Dolores Rueda-Illescas; Blas Gil-Extremera; Leticia Soriano-Carrascosa; Trinidad Alonso-Morales; Francisco García-Pérez; José García-Chicano; Juan de Dios Luna del Castillo
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.